Business Wire

UniPrint Partners with Healthcare IT Security Leader, Imprivata, to Enable Clinicians To Securely Print Protected Health Information

Del

UniPrint.net Corp., the world leader in printing virtualization, today announced a partnership with Imprivata®, the healthcare IT security company. UniPrint.net has joined the Imprivata Developer Partner (IDP) program, utilizing the Imprivata OneSign® Print Connector to establish connectivity between UniPrint’s™ patented Universal Printer Driver and Virtual Print Queue, and Imprivata OneSign. This integrated solution enables clinicians that use virtual desktops, to securely and conveniently print Protected Health Information (PHI) to any printer, by using the same proximity card they use to log in and securely access patient data. The joint solution increases security and compliance for healthcare providers by eliminating the printing of private health information on unattended printers.

Traditionally, location-based printing has been a challenge for even the most efficient hospitals. Healthcare professionals may inadvertently send prescriptions and private patient data to print on the wrong printer or a printer in a different facility, potentially exposing PHI and violating regulatory requirements.

David Fung, CEO of UniPrint.net comments, “Imprivata OneSign streamlines access, giving healthcare providers increased productivity, better compliance, stronger security, and reduced IT costs. Caregivers can now spend more time with patients and less time signing on to systems. When Imprivata OneSign is deployed in a virtual environment, a user’s desktop follows them as they roam around the workplace. An essential part of that workflow optimization is enabling secure, on demand printing to the correct printer. With a proven track record in healthcare, UniPrint is ideally suited to provide mobile healthcare workers with the ability to conveniently and securely print documents.”

Imprivata OneSign gives millions of care providers fast and secure No Click Access® to the applications and patient information they need, whenever and wherever they need it. By integrating with the

Imprivata OneSign Print Connector, UniPrint’s Universal Printer Driver and Virtual Print Queue leverages Imprivata OneSign’s clinical identity and authentication policy management capabilities and offers error-free, secure mobile printing on demand. Clinicians can print their documents using the same proximity card they use to securely access any endpoint and patient records.

“When healthcare providers are dealing with confidential patient information, they need a trusted, proven solution to address their secure printing needs,” said Clay Ritchey, Chief Marketing Officer at Imprivata. “Printing is often an overlooked vulnerability in healthcare organizations and we’re pleased that UniPrint is able to provide the secure printing workflow within Imprivata OneSign to add another layer of security for our joint customers.”

The solution will be introduced at the upcoming VMworld Conference in Las Vegas, USA, August 28-31. Come by the UniPrint Booth #657 to view a product demo, or to the Imprivata Booth #862 for additional information. Alternatively, visit www.uniprint.net to learn more about UniPrint.net, or book a free demo of our Healthcare Printing Suite.

About UniPrint.net:
UniPrint.net is the recognized leader in printing virtualization. The newest solution in UniPrint’s patented, award-winning product line, UniPrint Infinity is the industry’s first truly secure enterprise-wide solution for any computing environment. Enabling anywhere, anytime, and any device secure pull printing, UniPrint Infinity comes with a proven ROI through its statistics module, print document archiving functionality, secure mobile printing modules, and high availability setup with load balancing capability. UniPrint Infinity replaces all manufacturer printer drivers with a single PDF generator to promote faster, more efficient printing, helping organizations to improve both productivity and return on investments.

UniPrint™ and UniPrint Infinity™ are the trademarks of UniPrint.net Corp. All other trademarks and registered trademarks are properties of their respective owners.

About Imprivata:
Imprivata® (NYSE: IMPR), the healthcare IT security company, provides healthcare organizations globally with a security and identity platform that delivers authentication management, fast access to patient information, secure communications, and positive patient identification. Imprivata enables care providers to securely and efficiently access, communicate, and transact patient health information to address critical compliance and security challenges while improving productivity and the patient experience. For more information, please visit www.imprivata.com.

Contact information

UniPrint.net
Katherine Cheung, +1-416-503-9800 x 8586
Marketing Manager
Katherine.cheung@uniprint.net
or
Imprivata
John Hallock, 617-615-7712
jhallock@imprivata.com
or
Imprivata
Kerry Pillion, 781-761-1452
kpillion@imprivata.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00Pressemelding

ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number

GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01Pressemelding

GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No

AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45Pressemelding

AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun

Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30Pressemelding

Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti

Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30Pressemelding

Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult

Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom